Helicobacter pylori: A review

American Journal of Therapeutics

Volumn 5, Issue 4, 1998, Pages 253-261

  Wood, David W ^a   Block, Kevin P ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Gastroenterology Division   (United States)

Author keywords

Gastric carcinoma; Gastritis; Helicobacter pylori; Peptic ulcer disease

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; HELIDAC; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; RANITIDINE BISMUTH CITRATE; TETRACYCLINE; UNCLASSIFIED DRUG;

BACTERIAL VIRULENCE; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DRUG COST; GASTRITIS; GASTROINTESTINAL INFECTION; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; STOMACH CARCINOMA;

EID: 0031855660     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199807000-00008     Document Type: Review

References (76)

1. Warren JR: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-1275 (Letter).
2. Coghlan JG, Gilligan D, Humphries H, et al: Campylobacter pylori and recurrence of duodenal ulcers: A 12-month follow up study. Lancet 1987;2:1109-1111.
3. Marshall BJ, Goodwin CS, Warren JR, et al: Prospective double-blind trial of duodenal ulcer relapse after eradication of campylobacter pylori. Lancet 1988;2:1437-1142.
4. NIH consensus conference: Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-69.
5. Goodwin CS, Worsley BW: The Helicobacter genus: The history of Helicobacter pylori and taxonomy of current species. In: Helicobacter pylori: Biology and Clinical Practice. (Eds. Goodwin CS, Worsley BW), CRC Press, Baco Raton, FL, 1993, pp 1-15.
6. Pounder RE, Ng D: The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 1995;9(Suppl 2):33-39.
7. Hu PJ, Zhou MH, Chien M, et al: Helicobacter pylori associated with high prevalence of peptic ulcer disease and a low prevalence of gastric adenocarcinoma in a developing country. Gut 1995;36:198-202.
8. Mobley HLT: Defining Helicobacter pylori as a pathogen: Strain heterogenicity and virulence. Am J Med 1996;100(Suppl 5a):2-9.
9. Crabtree JE, Taylor JD, Wyatt JI, et al: Mucosal IgA recognition of Helicobacter pylori 120kDa protein, peptic ulceration, and gastric pathology. Lancet 1991;338:332-335.
10. Boren T, Falk P, Rath K, et al: Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 1993;262:1892-1895.
11. Cave DR: Transmission and epidemiology of Helicobacter pylori. Am J Med 1996;100(Suppl 5a):12-17.
12. Wilhoite SL, Ferguson DA, Soike DR, et al: Increased prevalence of Helicobacter pylori antibodies in nurses. Arch Intern Med 1993;153:708-712.
13. Ferguson D, Li C, Patel N, et al: Isolation of Helicobacter pylori from saliva. J Clin Microbiol 1993;31:2802-2804.
14. Nguyen A, Engstrand L, Genta R, et al: Detection of Helicobacter pylori in dental plaque by reverse transcription polymerase chain reaction. J Clin Microbiol 1993;31:783-787.
15. Graham DY, Malaty HM, Evans DO, et al: Epidemiology of Helicobacter pylori in an asymptomatic population in the U.S.: Effect of age, race, and socioeconomic status. Gastroenterology 1991;100:1495-1501.
16. Marshall BJ, Armstrong JA, McGechie DB, et al: Attempt to fulfill Koch's postulates for pyloric campylobacter. Med J Aust 1985;142:436-139.
17. Morris AJ, Nicholson GI: Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987;82:192-199.
18. McNulty CAM: Bismuth subsalicylate in the treatment of gastritis due to Campylobacter pylori. Rev Infect Dis 1990;12(Suppl 1):94-98.
19. Chamberlain CE, Peura DA: Campylobacter pylori: Is peptic disease a bacterial infection? Arch Intern Med 1990;150:951-955.
20. Borody TJ, Cole P, Noonan S, et al: Recurrence of duodenal ulcer and campylobacter pylori infection after eradication. Med J Aust 1989;151:431-435.
21. Marshal BJ: Helicobacter pylori. Am J Gastroenterol 1994;89:S116-S128.
22. Eurogast Study Group: An international association between Helicobacter pylori infection and gastric carcinoma. Lancet 1993;341:1359-1362.
23. Parsonnet J, Friedman GD, Vandersteen DP, et al: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-1131.
24. International Agency for Research on Cancer: Shistosomes, liver flukes, and Helicobacter pylori. IARC Sci Publ 1994;61:177-241.
25. Roggero F, Zucca E, Pinotti G, et al: Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995;122:767-769.
26. Mendall MA, Goggin PM, Molincaux R, et al: Relation of Helicobacter pylori infection and coronary artery disease. Br Heart J 1994;71:437-439.
27. Rebora A, Drago F, Picciotto A: Helicobacter pylori in patients with rosacea. Am J Gastroenterol 1994;89:1603-1604.
28. Perez-Perez G, Dworkin B, Chodos J, et al: Campylobacter pylori antibodies in humans. Ann Intern Med 1988; 109:11-17.
29. Cutler AF: Testing for Helicobacter pylori in clinical practice. Am J Med 1996;100(Suppl 5a):35-39.
30. Shimoyoma T, Fukuda S, Fukuda Y, et al: Validity of various diagnostic tests to evaluate care of Helicobacter pylori infection. Gastroenterol J 1996;31:171-174.
31. Klein PD, Malaty KM, Martin R, et al: Noninvasive detection of Helicobacter pylori infection in clinical practice: The 13-C urea breath test. Am J Gastroenterol 1996; 91:690-698.
32. Cutler AF, Havstad S, Ma C, et al: Accuracy of invasive and noninvasive test to diagnose Helicobacter pylori infection. Gastroenterology 1995;109:136-141.
33. Barthel JS, Everett ED: Diagnosis of Campylobacter pylori infection: The gold standard and the alternatives. Rev Infect Dis 1990;12(Suppl):107-114.
34. Graham DY, Ramirez FC: Omeprazole as an adjuvant to antimicrobial therapy for eradication of Helicobacter pylori infection. Curr Ther Res 1994;55:213-219.
35. Graham DY: 3 drugs or 2; 2 weeks or 1: The ideal treatment for Helicobacter pylori. American Gastroenterology Association '95 Conference, May 15, 1995.
36. Tytgat GNJ, Ranus EAJ, Langenberg W, et al: Long term follow-up of Campylobacter pylori association gastritis after treatment with colloidal bismuth subnitrate and/or amoxicillin. Gastroenterology 1988;94:A469.
37. Patchett S, Beattie S, Leen E, et al: Eradication of Helicobacter pylori and symptoms of non-ulcer dyspepsia. BMJ 1991;303:1238-1240.
38. Tatsata M, Ishikawa H, Iishi H, et al: Reduction of gastric ulcer recurrence after suppression of helicobacter pylori by Cefixime. Gut 1990;31:973-976.
39. Peterson WL, Graham DY, Marshall B, et al: Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized, double-blind trial. Am J Gastroenterol 1993;88:1860-1864.
40. Chiba N, Rao BV, Rademaker J, et al: Meta analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1997;87:1716-1727.
41. Marshall BJ, Dye KR, Plankey M, et al: Eradication of Campylobacter pylori infection with bismuth subsalicylate and antibiotic combinations. Am J Gastroenterol 1988;83:A74.
42. Graham DY: Peptic ulcer. In: Current Practice of Medicine. (Ed. Bone RC), Churchill-Livingstone, New York, NY, 1996.
43. Olson C, Edmonds A: Primary susceptibility of Helicobacter pylori to clarithromycin compared to metronidazole in patients with duodenal ulcer association with Helicobacter pylori infection. Gut 1995;37(Suppl 2):A814.
44. Chiba N, Wilkinson JM, Hunt R: Clarithromycin or amoxicillin dual and triple therapies in Helicobacter pylori eradication: A meta-analysis. Gut 1995;37:T124.
45. Mohammed H, Chiba N, Wilkinson J, et al: Eradication of Helicobacter pylori. A meta-analysis. Gastroenterology 1994;106:A142.
46. Truesdale R, Chamberlain C, Martin D, et al: Long-term follow up and antibody response to treatment of patients with Helicobacter pylori. Gastroenterology 1990; 98:A140.
47. Borody T, George L, Brandl S, et al: Helicobacter pylori eradication with doxycycline metro-bismuth subcitrate triple therapy. Scand J Gastroenterol 1992;27:281-284.
48. Lind T, Veldhuyzen V, Unge P, et al: The MACH study: Optimal one-week treatment for Helicobacter pylori defined? Gut 1995;37(Suppl 1):A186.
49. Mauch F, Bode G: Identification and characterization of an ATPase system: Helicobacter pylori and effect of proton pump inhibitors. Am J Gastroenterol 1993;88:1801-1802.
50. Van Zanten S, Boldie J, Hollingsworth J, et al: Secretion of intravenously administered antibiotics in gastric juice: Implications for management of Helicobacter pylori. J Clin Pathol 1992;45:225-227.
51. Lind T, Veldhuyzen ZEN, Van Zuraten S, et al: Eradication of Helicobacter pylori using one week triple therapies combining omeprazole with two antimicrobies: The Mach 1 study. Helicobacter 1996;1:138-144.
52. Moayyedi P, Axon A: Efficacy of a new one week triple therapy regime in eradicating Helicobacter pylori. Gut 1994;35:S62.
53. Bardhan K, Dekkers C, Lam S, et al: GR122311x (ranitidine bismuth citrate) a new drug for the treatment of duodenal ulcer. Aliment Pharmacol Ther 1995;9:497-506.
54. Graham D, Lew G, Evans DG, et al: Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. Ann Intern Med 1991;115:266-269.
55. Weil J, Bell G, Powell K, et al: Helicobacter pylori infection treated with tripotassium dicitrate bismuth and metronidazole combination. Aliment Pharmacol Ther 1990;4:651-657.
56. Penston J: Review article: Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994;8:369-389.
57. Lambert J, Lin S, Borromeo M, et al: Eradication of Helicobacter pylori with colloidal bismuth subcitrate/ antibiotic combinations. Gastroenterology 1990;98:A74.
58. Hunt R: Eradication of Helicobacter pylori infection. Am J Med 1996;100(Suppl 5a):425-505.
59. Fontham E, Bernardo R, Perez A, et al: Determinants of Helicobacter pylori infection and chronic gastritis. Am J Gastroenterol 1995;90:1094-1101.
60. Schubert T, Bologna S, Nensey Y, et al: Ulcer risk factors: Interactions between Helicobacter pylori infection, NSAID use, and age. Am J Med 1993;94:413-418.
61. Peura D: Helicobacter and ulcerogenesis. Am J Med 1996;100(Suppl 5a):19-26.
62. McNulty C, Dent J, Ford G, et al: Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother 1988;22:729-735.
63. Rademalter J, Zettel L, Jacobsen K, et al: Gastric juice immunoglobulins: Immunophysiological interaction in Helicobacter pylori infection. Gastroenterlogy 1993;104: A176.
64. Terada S, Negayama K, Kawanishi K: Neutrophil migration into the mucous layer in Helicobacter pylori association gastritis. Eur J Gastroenterol Hepatol 1993;5:454-457.
65. Bell G, Powell K, Burridge S, et al: Experience with omeprazole in combination with either amoxycillin or colloidal bismuth subcitrate in patients with metronidazole resistant Helicobacter pylori. Eur J Gastroenterol Hepatol 1991;3:923-926.
66. Bell G, Powell K, Burridge S, et al: Experience with "triple" anti Helicobacter pylori eradication therapy: Side effects - the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992;6:427-435.
67. Vakil N, Fennerty B: The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease. Am J Med 1994;100(Suppl 5A):60-64.
68. Smith M, Edwards D: The influence of microaerophilia and anaerobiosis on metronidazole uptake in Helicobacter pylori. J Antimicrob Chemother 1995;36:453-461.
69. Savarino V, Mela GS, Vigneri S, et al: Helicobacter pylori eradication and reinfection. Lancet 1995;345:1646-1648.
70. Chen M, Lee A, Hazell S: Immunization against gastric Helicobacter pylori infection in a mouse/Helicobacter Felis model. Lancet 1992;339:1120-1221.
71. Kreiss C, Buelin T, Cosma M, et al: Safety of oral immunization with recombinant urease in patients with helicobacter pylori infection. Lancet 1996;347:1630-1631.
72. Lee A, Buck F: Vaccination and mucosal responses to Helicobacter pylori infection. Aliment Pharmacol Ther 1996;10(suppl 1):129-138.
73. U.S. Department of Health and Human Services: Stomach and Duodenal Ulcers. National Institute of Diabetes and Digestion and Kidney diseases, NIM, Bethesda, MD, 1995, pp 95-138.
74. Imperiale T, Spiroff T, Cebul R, et al: A cost analysis of alternative treatments for duodenal ulcer. Ann Intern Med 1995;123:665-672.
75. Taylor J, Zagari M, Murphy K, et al: Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch Intern Med 1997;157:87-97.
76. 2 receptor antagonists and duodenal ulcer recurrence: Analysis of efficacy and commentary on safety, costs, and patient selection. J Gastroenterol 1987; 82:1242-1249.